The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder

Scott W. Shelfo, Mark S. Soloway

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Successful management of transitional-cell carcinoma of the urinary bladder is greatly dependent upon regular surveillance and early detection of persistent or recurrent carcinoma. The development of a highly sensitive urinary test for the detection of transitional-cell carcinoma of the bladder could have a dramatic impact on our ability to diagnose and monitor bladder cancer patients as well as influence the treatment outcome. The urinary level of the nuclear matrix protein. NMP22. has been found to be elevated in patients with urothelial malignancy. This has prompted the development of an immunoassay to quantitate urinary NMP22 and use it as a cancer-specific marker. We provide a summary of the studies completed with the immunoassay for urinary NMP22 as an indicator for the presence of transitional-cell carcinoma and compare the results with those obtained using other screening modalities.

Original languageEnglish
Pages (from-to)107-111
Number of pages5
JournalWorld Journal of Urology
Volume15
Issue number2
StatePublished - Dec 1 1997
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder Neoplasms
Immunoassay
Urinary Bladder
Nuclear Matrix-Associated Proteins
Neoplasms
Carcinoma
nuclear matrix protein 22

ASJC Scopus subject areas

  • Urology

Cite this

The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. / Shelfo, Scott W.; Soloway, Mark S.

In: World Journal of Urology, Vol. 15, No. 2, 01.12.1997, p. 107-111.

Research output: Contribution to journalArticle

@article{d92e62d0d68643e3a45887e1004a1bbf,
title = "The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder",
abstract = "Successful management of transitional-cell carcinoma of the urinary bladder is greatly dependent upon regular surveillance and early detection of persistent or recurrent carcinoma. The development of a highly sensitive urinary test for the detection of transitional-cell carcinoma of the bladder could have a dramatic impact on our ability to diagnose and monitor bladder cancer patients as well as influence the treatment outcome. The urinary level of the nuclear matrix protein. NMP22. has been found to be elevated in patients with urothelial malignancy. This has prompted the development of an immunoassay to quantitate urinary NMP22 and use it as a cancer-specific marker. We provide a summary of the studies completed with the immunoassay for urinary NMP22 as an indicator for the presence of transitional-cell carcinoma and compare the results with those obtained using other screening modalities.",
author = "Shelfo, {Scott W.} and Soloway, {Mark S.}",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "15",
pages = "107--111",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder

AU - Shelfo, Scott W.

AU - Soloway, Mark S.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Successful management of transitional-cell carcinoma of the urinary bladder is greatly dependent upon regular surveillance and early detection of persistent or recurrent carcinoma. The development of a highly sensitive urinary test for the detection of transitional-cell carcinoma of the bladder could have a dramatic impact on our ability to diagnose and monitor bladder cancer patients as well as influence the treatment outcome. The urinary level of the nuclear matrix protein. NMP22. has been found to be elevated in patients with urothelial malignancy. This has prompted the development of an immunoassay to quantitate urinary NMP22 and use it as a cancer-specific marker. We provide a summary of the studies completed with the immunoassay for urinary NMP22 as an indicator for the presence of transitional-cell carcinoma and compare the results with those obtained using other screening modalities.

AB - Successful management of transitional-cell carcinoma of the urinary bladder is greatly dependent upon regular surveillance and early detection of persistent or recurrent carcinoma. The development of a highly sensitive urinary test for the detection of transitional-cell carcinoma of the bladder could have a dramatic impact on our ability to diagnose and monitor bladder cancer patients as well as influence the treatment outcome. The urinary level of the nuclear matrix protein. NMP22. has been found to be elevated in patients with urothelial malignancy. This has prompted the development of an immunoassay to quantitate urinary NMP22 and use it as a cancer-specific marker. We provide a summary of the studies completed with the immunoassay for urinary NMP22 as an indicator for the presence of transitional-cell carcinoma and compare the results with those obtained using other screening modalities.

UR - http://www.scopus.com/inward/record.url?scp=0030631308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030631308&partnerID=8YFLogxK

M3 - Article

C2 - 9144900

AN - SCOPUS:0030631308

VL - 15

SP - 107

EP - 111

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 2

ER -